Article
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
International journal of hematology - 1 Aug 2022
Marumo Atsushi, Wakita Satoshi, Morita Kaoru, Oh Iekuni, Kako Shinichi, Toya Takashi, Najima Yuho, Doki Noriko, Kanda Junya, Kuroda Junya, Mori Shinichiro, Satake Atsushi, Usuki Kensuke, Uoshima Nobuhiko, Kobayashi Yutaka, Kawata Eri, Nagao Yuhei, Shono Katsuhiro, Shibusawa Motoharu, Tadokoro Jiro, Hagihara Masao, Uchiyama Hitoji, Kubota Yasushi, Kimura Shinya, Motomura Sayuri, Hashimoto Akiko, Muto Hideharu, Sato Eriko, Ogata Masao, Mitsuhashi Kenjiro, Ando Jun, Date Kenta, Fujiwara Yusuke, Terada Kazuki, Yui Shunsuke, Arai Kunihito, Kitano Tomoaki, Miyata Miho, Ohashi Kazuteru, Kanda Yoshinobu, Yamaguchi Hiroki
Abstract excerpt
Recent studies have reported that measurable residual disease (MRD) analysis using NPM1 mutations helps determine whether allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated in acute myeloid leukemia (AML) patients. However, the optimal timing and cutoff value for measuring MRD using genomic DNA remain undetermined. This study aimed to investigate the optimal timing and cutoff value to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.